Currently Viewing:
The American Journal of Managed Care April 2017
Physician Variation in Lung Cancer Treatment at the End of Life
Jonas B. Green, MD, MPH, MSHS; Martin F. Shapiro, MD, PhD; Susan L. Ettner, PhD; Jennifer Malin, MD, PhD; Alfonso Ang, PhD; and Mitchell D. Wong, MD, PhD
Real-World Evidence and the Behavioral Economics of Physician Prescribing
Bruce Feinberg, DO
Provider Type and Management of Common Visits in Primary Care
Douglas W. Roblin, PhD; Hangsheng Liu, PhD; Lee F. Cromwell, MS; Michael Robbins, PhD; Brandi E. Robinson, MPH; David Auerbach, PhD; and Ateev Mehrotra, MD, MPH
Concentration of High-Cost Patients in Hospitals and Markets
Nancy D. Beaulieu, PhD; Karen E. Joynt, MD, MPH; Robert Wild, MS, MPH; and Ashish K. Jha, MD, MPH
Currently Reading
The Relationship Between Adherence and Total Spending Among Medicare Beneficiaries With Type 2 Diabetes
Joanna P. MacEwan, PhD; John J. Sheehan, PhD; Wes Yin, PhD; Jacqueline Vanderpuye-Orgle, PhD; Jeffrey Sullivan, MS; Desi Peneva, MS; Iftekhar Kalsekar, PhD; and Anne L. Peters, MD
The Breathmobile Improves the Asthma Medication Ratio and Decreases Emergency Department Utilization
Tricia Morphew, MSc; Wendy Altamirano, MPH, MBA; Stanley L. Bassin, EdD; and Stanley P. Galant, MD
Patients' Preferences for Receiving Laboratory Test Results
Azam Sabahi, BS; Leila Ahmadian, PhD; Moghadameh Mirzaee, PhD; and Reza Khajouei, PhD
Medication Burden in Patients With Acute Coronary Syndromes
Eric A. Wright, PharmD, MPH; Steven R. Steinhubl, MD; J.B. Jones, PhD, MBA; Pinky Barua, MSc, MBA; Xiaowei Yan, PhD; Ryan Van Loan, BA; Glenda Frederick, BA; Durgesh Bhandary, MS; and David Cobden, Ph
Battling the Chargemaster: A Simple Remedy to Balance Billing for Unavoidable Out-of-Network Care
Barak D. Richman, JD, PhD; Nick Kitzman, JD; Arnold Milstein, MD, MPH; and Kevin A. Schulman, MD

The Relationship Between Adherence and Total Spending Among Medicare Beneficiaries With Type 2 Diabetes

Joanna P. MacEwan, PhD; John J. Sheehan, PhD; Wes Yin, PhD; Jacqueline Vanderpuye-Orgle, PhD; Jeffrey Sullivan, MS; Desi Peneva, MS; Iftekhar Kalsekar, PhD; and Anne L. Peters, MD
This study describes a widespread variation in medication adherence, pharmacy cost sharing, and medical spending. Increased cost sharing may decrease adherence and increase total diabetes spending.
This study corroborates previous research and suggests that increasing adherence among Medicare beneficiaries with T2D could generate significant cost savings.17 The use of pharmacy cost sharing in Medicare has gone up since the introduction of Medicare Part D, which extended pharmacy benefit coverage and increased pharmaceutical utilization,29 but the availability of generic drugs has prevented significant increases in OOP spending. If this cost-sharing trend continues, adherence may fall and any savings on pharmacy spending could be offset by increased medical spending.16 Recent proposals to limit annual OOP spending for Medicare beneficiaries would reduce the financial burden on high-spend Medicare beneficiaries with T2D, potentially improving medication adherence and health outcomes.30

Limitations

This study has certain limitations. The analysis was descriptive, with data randomly drawn from an administrative claims database representing the years 2006 to 2009. Although the levels of pharmacy and medical spending may have changed since 2009, our qualitative results and the correlations between cost sharing, adherence, and medical spending should not be impaired by the age of the data, as many similar studies have found the same relationships in other patient samples and time periods.4-14 Additionally, because the study drew from the Medicare database, and because only patients 65 years or older at the time of the first observed T2D diagnosis claim were included, the mean age of the sample (74 years) was higher than the average age of T2D diagnosis (54 years) in the United States.31 Last, only limited medical history is available for patients in claims data research, thereby increasing the potential for confounding, and the date of patients’ initial T2D diagnosis could not be determined with certainty.

CONCLUSIONS

This study has several implications. First, the study results demonstrates the existence of a skew in spending on T2D treatment. Medicare patients in the highest deciles of total spending had dramatically higher total and medical spending, clearly indicating that most spending on diabetes-related treatment is from medical—and not pharmacy—spending among a subset of high-cost patients. In addition, the study expands on available studies of patients with employer-sponsored insurance to demonstrate that improved adherence is related to reduced resource use and spending in Medicare beneficiaries with T2D and suggest that interventions aimed at improving adherence among high-cost patients have the greatest potential to reduce health expenditures. Most importantly, the study results confirm the negative connection established in the existing literature between cost sharing and medication adherence, which varied widely among Medicare beneficiaries with T2D.4-14 If pharmacy cost-sharing programs decrease medication adherence, initiatives that promote pharmacy cost sharing may unintentionally increase the risk of medical complications offsetting some (or in targeting cases, all) of the savings associated with lower pharmaceutical spending. 

Author Affiliations: Precision Health Economics (JPM, JV-O, JS, DP), Los Angeles, CA; AstraZeneca (JJS, IK), Fort Washington, PA; University of California, Los Angeles (WY), Los Angeles, CA; University of Southern California (ALP), Los Angeles, CA.

Source of Funding: This study was supported by AstraZeneca.

Author Disclosures: Dr MacEwan, Mr Sullivan, and Ms Peneva are employees of Precision Health Economics (PHE), which is a consultant for biotech/pharma companies and was compensated by AstraZeneca to perform the study. Dr Vanderpuye-Orgle was an employee of PHE during the time of the study and is currently employed by Amgen. Dr Yin is a consultant for PHE. Dr Sheehan has been employed by AstraZeneca, and Dr Kalsekar has been employed by and holds stock in AstraZeneca and Johnson & Johnson, which manufacture drugs for the treatment of diabetes. Dr Peters has been a consultant and grant recipient from numerous pharmaceutical companies including AstraZeneca, and receives editorial fees from Medscape.

Authorship Information: Concept and design (JPM, JJS, WY, JV-O, JS, IK, ALP); acquisition of data (JS, IK); analysis and interpretation of data (JPM, JJS, WY, JV-O, JS, DP, IK); drafting of the manuscript (JPM, WY, DP); critical revision of the manuscript for important intellectual content (JPM, JJS, WY, JS, ALP); statistical analysis (WY, JS); provision of patients or study materials (ALP); obtaining funding (JJS, IK); administrative, technical, or logistic support (DP, IK); and supervision (JJS, WY, JV-O, IK).

Address Correspondence to: Joanna P. MacEwan, PhD, Precision Health Economics, 11100 Santa Monica Blvd, Suite 500, Los Angeles, CA 90025. E-mail: joanna.macewan@pheconomics.com. 
REFERENCES

1. National diabetes statistics report. CDC website. https://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Published October 24, 2014. Accessed January 21, 2015.

2. American Diabetes Association. Economic costs of diabetes in the US in 2012. Diabetes Care. 2013;36(4):1033-1046. doi: 10.2337/dc12-2625.

3. American Diabetes Association. Economic costs of diabetes in the US in 2007. Diabetes Care. 2008;31(3):596-615. doi: 10.2337/dc08-9017.

4. Goldman DP, Joyce GF, Zheng Y. Prescription drug cost sharing: associations with medication and medical utilization and spending and health. JAMA. 2007;298(1):61-69.

5. Goldman DP, Joyce GF, Escarce JJ, et al. Pharmacy benefits and the use of drugs by the chronically ill. JAMA. 2004;291(19):2344-2350.

6. Sokol MC, McGuigan KA, Verbrugge RR, Epstein RS. Impact of medication adherence on hospitalization risk and healthcare cost. Med Care. 2005;43(6):521-530.

7. Huskamp HA, Deverka PA, Epstein AM, Epstein RS, McGuigan KA, Frank RG. The effect of incentive-based formularies on prescription-drug utilization and spending. N Engl J Med. 2003;349(23):2224-2232.

8. Sinnott SJ, Buckley C, O’Riordan D, Bradley C, Whelton H. The effect of copayments for prescriptions on adherence to prescription medicines in publicly insured populations; a systematic review and meta-analysis. PLoS One. 2013;8(5):e64914. doi: 10.1371/journal.pone.0064914.

9. Gibson TB, Ozminkowski RJ, Goetzel RZ. The effects of prescription drug cost sharing: a review of the evidence. Am J Manag Care. 2005;11(11):730-740.

10. Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care. 2006;12(1):21-28.

11. Gibson TB, Mahoney J, Ranghell K, Cherney BJ, McElwee N. Value-based insurance plus disease management increased medication use and produced savings. Health Aff (Millwood). 2011;30(1):100-108. doi: 10.1377/hlthaff.2010.0896.

12. Choudhry NK, Fischer MA, Avorn JL, et al. The impact of reducing cardiovascular medication copayments on health spending and resource utilization. J Am Coll Cardiol. 2012;60(18):1817-1824. doi: 10.1016/j.jacc.2012.06.050.

13. Chernew ME, Shah MR, Wegh A, et al. Impact of decreasing copayments on medication adherence within a disease management environment. Health Aff (Millwood). 2008;27(1):103-112. doi: 10.1377/hlthaff.27.1.103.

14. Maciejewski ML, Farley JF, Parker J, Wansink D. Copayment reductions generate greater medication adherence in targeted patients. Health Aff (Millwood). 2010;29(11):2002-2008. doi: 10.1377/hlthaff.2010.0571.

15. Ruelas V, Roybal GM, Lu Y, Goldman D, Peters A. Clinical and behavioral correlates of achieving and maintaining glycemic targets in an underserved population with type 2 diabetes. Diabetes Care. 2009;32(1):54-56. doi: 10.2337/dc08-1234.

16. Hoadley J, Cubanski J, Neuman T. Medicare Part D at ten years: the 2015 marketplace and key trends, 2006-2015. Kaiser Family Foundation website. http://kff.org/medicare/report/medicare-part-d-at-ten-years-the-2015-marketplace-and-key-trends-2006-2015/. Published October 5, 2015. Accessed January 9, 2015.

17. Roebuck MC. Medical cost offsets from prescription drug utilization among Medicare beneficiaries. J Manag Care Spec Pharm. 2014;20(10):994-995.

18. Bron M, Guerin A, Latremouille-Viau D, et al. Distribution and drivers of costs in type 2 diabetes mellitus treated with oral hypoglycemic agents: a retrospective claims data analysis. J Med Econ. 2014;17(9):646-657. doi: 10.3111/13696998.2014.925905.

19. Meyers JL, Parasuraman S, Bell KF, Graham JP, Candrilli SD. The high-cost, type 2 diabetes mellitus patient: an analysis of managed care administrative data. Arch Public Health. 2014;72(1):6. doi: 10.1186/2049-3258-72-6.

20. Avorn J, Monette J, Lacour A, et al. Persistence of use of lipid-lowering medications: a cross-national study. JAMA. 1998;279(18):1458-1462.

21. Blandford L, Dans PE, Ober JD, Wheelock C. Analyzing variations in medication compliance related to individual drug, drug class, and prescribing physician. J Manag Care Spec Pharm. 1999;5(1):47-51. doi: 10.18553/jmcp.1999.5.1.47.

22. Goldman DP, Joyce GF, Karaca-Mandic P. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. Am J Manag Care. 2006;12(1):21-28.

23. Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL. Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother. 2009;43(1):36-44. doi: 10.1345/aph.1K671.

24. Schultz JS, O’Donnell JC, McDonough KL, Sasane R, Meyer J. Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care. 2005;11(5):306-312.

25. Chronic conditions among Medicare beneficiaries, chartbook: 2012 edition. CMS website. https://www.cms.gov/research-statistics-data-and-systems/statistics-trends-and-reports/chronic-conditions/downloads/2012chartbook.pdf. Published October 2012. Accessed January 9, 2015.

26. An J, Nichol MB. Multiple medication adherence and its effect on clinical outcomes among patients with comorbid type 2 diabetes and hypertension. Med Care. 2013;51(10):879-887. doi: 10.1097/MLR.0b013e31829fa8ed.

27. Asche C, LaFleur J, Conner C. A review of diabetes treatment adherence and the association with clinical and economic outcomes. Clin Ther. 2011;33(1):74-109. doi: 10.1016/j.clinthera.2011.01.019.

28. Goldman DP, Smith JP. Can patient self-management help explain the SES health gradient? Proc Natl Acad Sci USA. 2002;99(16):10929-10934.

29. Yin W, Basu A, Zhang JX, Rabbani A, Meltzer DO, Alexander GC. The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Ann Intern Med. 2008;148(3):169-177.

30. Cubanski J, Neuman T, Levinson Z. Adding an out-of-pocket spending maximum to Medicare: implementation issues and challenges. Kaiser Family Foundation website. https://kaiserfamilyfoundation.files.wordpress.com/2014/02/8525-adding-an-out-of-pocket-spending-maximum-to-medicare.pdf. Published February 2014. Accessed January 22, 2015.

31. Mean and median age at diagnosis of diabetes among adult incident cases aged 18-79 years, United States, 1997-2011. CDC website. https://www.cdc.gov/diabetes/statistics/age/fig2.htm. Updated December 1, 2015. Accessed January 22, 2015. 
PDF
 
Copyright AJMC 2006-2018 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!